CRDF Global is accepting proposals on behalf of the Division of AIDS at the National Institute of Allergy and Infectious Diseases (NIAID) to fund collaborative global HIV/TB research projects across the Regional Prospective Observational Research in TB (RePORT) International consortia the 19 Centers for AIDS Research (CFAR) allowing for work to extend across the two programs.
This supplemental funding is aimed at supporting ongoing projects by participating members of CFARs and the RePORT consortia to implement cross cutting research activities addressing biomarker discovery that is of special importance to TB/HIV co-infections. Eligible applicants must be investigators from currently active RePORT and CFAR sites.
Please see attached documents for the RFP and Application Forms.
For all inquiries, please contact:
Christopher Maxwell, CRDF Global email@example.com
Bridget Woolery, CRDF Global firstname.lastname@example.org
Candice Beaubien (NIH/NIAID) email@example.com
Elaine Wong (NIH/NIAID) firstname.lastname@example.org
Sudha Srinivasan, (NIH/NIAID) email@example.com
Roxana Rustomjee, (NIH/NIAID) firstname.lastname@example.org
"Health Disparities Populations Series: LGBT State of the Science and Caring"
When: November 15-16, 2018
Where: Westin in Pasadena.
Learn about the current HIV testing algorithms and their limitations and new HIV diagnostic tests that are on the horizon and how they may impact the HIV diagnostic algorithm.
When: November 16th, 2018; 10am-3pm
Where: San Diego Marriott La Jolla.
RFA-CA-18-018 “Prevention of HPV-related Cancers in HIV-infected individuals: United States-Latin American-Caribbean Clinical Trials Network: Partnership Centers (U54 Clinical Trial Required)”
The Application Due Date is November 15, 2018 and the Letter of Intent (optional) due date is October 15, 2018.
PAR-17-471 "Detection of HIV for Self-Testing (R61/R33)"
The Application Due Date is December 6, 2018
This NIH Funding Opportunity Announcement (FOA) will support development of innovative research strategies feasible as a self-test to detect HIV in the earliest stage of initial HIV infection (ideally less than 2 weeks post-infection) and/or to monitor viral rebound after stopping or developing resistance to antiretroviral therapy.
RFA-DA-19-009 "Modeling HIV Neuropathology Using Microglia from Human iPSC and Cerebral Organoids (R01 Clinical Trial Not Allowed)"
The Application Due Date is December 18, 2018
NIDA has published a new RFA on HIV/AIDS research, RFA-DA-19-009, titled Modeling HIV Neuropathology Using Microglia from Human iPSC and Cerebral Organoids. The mechanism of the support is R01 and R21. This RFA invites research grant applications to study the cellular and molecular mechanisms delineating the neuropathophysiology of HIV-associated neurological disorders (HAND) in the setting of long-term combination antiretroviral therapy (cART) conditions using induced microglia and cerebral organoids generated from patient derived induced pluripotent stem cell (iPSC) lines. It has a Letter of Intent Due Date of November 18, and a submission date of December 19, 2018.
Date/Time: Monday, November 19th, 2018; from 1:00pm – 2:00pm (EST)
Speaker: Nicholas Funderburg, PhD; Associate Professor at Ohio State University
Title: Myeloid Cell Activation: A Potential Contributor to CVD Risk in HIV Infection?
Registration Link: https://goo.gl/wgwGZY
The UCSF Center of Excellence for Transgender Health invites you to submit abstracts to the 2019 National Transgender Health Summit. This landmark program will present cutting edge research, evidence-based educational sessions, and training opportunities across many disciplines, and is the premiere national conference in transgender health.
Please carefully review the descriptions and abstract submission guidelines below before preparing your abstract.
Submission Deadline: November 21, 2018
The 2018 CFAR HIV Research Day will be held on Thursday, December 6, 2018 in the Medical Education and Telemedicine Building. Last year, more than 100 participants heard a dozen presentations on disparities in HIV prevention, treatment, and care. Learn more about this exciting one-day event! Also check the HIV Institute Facebook, Twitter, and Instagram feeds for updates.
Call for Abstracts!
If you are interested in submitting an abstract for Research Day, download the Call for Abstracts! to see the submission guidelines!
New in 2018: Emerging Investigator Prize! The best abstract by an emerging investigator will be scheduled for a 30-minute talk and the author will receive a $200 gift certificate to the UC San Diego Bookstore!
The PEER program is an international grants program that is made possible by a Cooperative Agreement between USAID and The National Academies of Sciences, Engineering, and Medicine. It is a 10-year program with a $100 million ceiling and was designed to support collaboration between foreign scientists and United States Government researchers. PEER-eligible countries may be found in the accompanying slides, along with examples of PEER projects with NIH partners.
The PEER Model invites local, in-country scientists to propose a research project that aligns with U. S. congressional priorities and country interests. Additional DC-based core funds are available to support projects deemed meritorious but are not necessarily aligned with the outlined research goals.
The 2018/2019 (Cycle 8) announcement will likely be the last call for projects. The solicitation and goals for Cycle 8 will be announced in the Fall on the PEER website. Pre-proposals will be due to the National Academies around mid-January and selected applicants will be invited to submit a full proposal, which will be due in the beginning of April. More information on the application process may be found here.
Those with questions regarding the program are encouraged to visit the program’s FAQ page.
More info: General PEER Slides 2018
The AFP for Prevention Symposium will be held on January 28-29, 2019. The location of the symposium will be at the Emory Conference Center in Atlanta, GA.
Stay tuned for more details about the symposium.
Improving Smoking Cessation Interventions among People Living with HIV (R01 Clinical Trial Optional)
Due date: January 8, 2019, by 5:00 PM
Improving Smoking Cessation Interventions among People Living with HIV (R21 Clinical Trial Optional)
Due date: January 8, 2019, by 5:00 PM
Here are the following grants:
Read more about it here!